The company is reaffirming the adjusted 2023 EPS guidance range of $5.55 to $5.75, and long-term adjusted EPS growth rate of 5% to 7% through 2027 off the 2023 midpoint of $5.65. Management does not forecast reported
Companies Reporting Before The Bell
• AstraZeneca (NASDAQ:AZN) is expected to report quarterly earnings at $0.67 per share on revenue of $11.21 billion.
The utility sector is generally credited as an “all-weather” investment, given its defensive nature and the steady returns it generates in the form of dividends.